Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Nexsen Targets Mid-2027 FDA Filing As Kidney Test Program Expands

Nexsen Limited (NXN) · Health care

NXN: $0.165 +3.13% · MC: $32M

Nexsen says its RenalSure kidney test is progressing towards a targeted US FDA submission in mid-2027, subject to development and clinical validation. It has also begun a feasibility study with GENSPEED on a complementary cartridge-based test, intended to broaden its offering for hospital monitoring; the company cites a global acute kidney injury diagnostics market forecast to grow from about US$1 billion to about US$2 billion by 2033.

Source announcements: 2026-11-06 09:39 to 2026-11-06 09:39 Sydney time
Story updated 2026-11-06 09:52 Sydney time
SourcesNexsen advances kidney diagnostics program
Comments